Infectologia

Covid-19: a mudança na política da Nova Zelândia é um avanço ou um retrocesso?

13 Out, 2021 | 12:51h

Covid-19: Is New Zealand’s switch in policy a step forward or a retreat? – The BMJ

Conteúdos relacionados:

New Zealand acknowledges it can no longer completely get rid of the coronavirus.

Why we must not allow COVID to become endemic in New Zealand – The Conversation

 

Comentário no Twitter

On 4 October New Zealand's prime minister announced that the country was shifting from a policy of elimination to a mitigation approach more in line with policies in other developed countries.

What comes next and what lessons have been learnt?https://t.co/Z62olXHzb9

— The BMJ (@bmj_latest) October 11, 2021

 

---

Por que amenizar as restrições por COVID pode propiciar um forte rebote da gripe – “Enquanto as restrições são flexibilizadas, outros vírus respiratórios estão voltando, de maneiras inesperadas.”

13 Out, 2021 | 12:50h

Why easing COVID restrictions could prompt a fierce flu rebound – Nature

---

Como o antiviral molnupiravir disparou na corrida por um medicamento contra COVID.

13 Out, 2021 | 12:48h

How antiviral pill molnupiravir shot ahead in the COVID drug hunt – Nature

Conteúdos relacionados:

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

---

Estudo randomizado por cluster | Intervenção de gestão de antibióticos reduziu, de modo seguro, o uso de antibióticos de amplo espectro em pacientes internados com pneumonia adquirida na comunidade moderadamente grave.

13 Out, 2021 | 12:28h

Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial – The Lancet Infectious Diseases (link para o resumo – $ para o texto completo)

---

Nova análise do Global Burden of Disease Study mostra depressão e ansiedade entre as principais causas mundiais de impacto de saúde, além de um aumento significativo decorrente da pandemia de COVID-19.

12 Out, 2021 | 11:24h

Comunicado de imprensa: New Global Burden of Disease analyses show depression and anxiety among the top causes of health burden worldwide, and a significant increase due to the COVID-19 pandemic – Institute for Health Metrics and Evaluation

Estudo original: Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic – The Lancet

Comentários:

Depression and anxiety disorders during the COVID-19 pandemic: knowns and unknowns – The Lancet

COVID-19 pandemic led to stark rise in depressive and anxiety disorders globally in 2020: study – The Lancet

Covid crisis dramatically worsened global mental health, study finds – The Guardian

 

Comentário no Twitter (fio – clique para saber mais)

✨🆕–The #COVID19 pandemic led to a stark rise in depressive and anxiety disorders globally in 2020 w/women & younger people most affected, according to a new study by our researchers & collaborators published today in @TheLancet. #GBDstudy #MentalHealth

»https://t.co/qXEDzn3idV pic.twitter.com/4xsofBXyvS

— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) October 8, 2021

 

---

Estudo randomizado | Dose terapêutica de heparina se mostrou superior à dose profilática ou à dose intermediária para tromboprofilaxia em pacientes de alto risco internados com COVID-19.

12 Out, 2021 | 11:22h

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial – JAMA Internal Medicine

Comentário convidado: Anticoagulant Therapy in Patients Hospitalized With COVID-19 – JAMA Internal Medicine

Estudos relacionados (alguns resultados conflitantes)

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

 

Comentário no Twitter

Thromboprophylaxis w therapeutic-dose LMWH reduced major thromboembolism and death by 32% compared with institutional standard heparin without increased major bleeding among #COVID19 inpatients with elevated D-dimers. The effect wasn't seen in ICU patients https://t.co/Wrgj2Ho5lv

— JAMA Internal Medicine (@JAMAInternalMed) October 7, 2021

 

---

Crianças estão perdendo dias de aula para a quarentena. Há um meio de mantê-las nas aulas – “Realizar testes frequentes poderia reduzir drasticamente a quarentena de contatos próximos.”

12 Out, 2021 | 11:20h

Kids are losing school days to quarantines. Here’s a way to keep them in classrooms – NPR

Estudo relacionado: Cluster RCT: Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission.

---

Bioética | O “problema do bonde” e a vacinação de jovens contra a COVID-19.

12 Out, 2021 | 11:18h

The Trolley Problem and Vaccinating Young People Against COVID-19 – Science-Based Medicine

---

[Preprint] COVID-19 em crianças, decorrente da cepa Delta do SARS-CoV-2, é semelhante à doença causada pela variante Alfa, com curta duração e sintomas similares.

12 Out, 2021 | 11:16h

Illness characteristics of COVID-19 in children infected with the SARS-CoV-2 Delta variant – medRxiv

 

Comentário no Twitter

Did you hear “Delta is different”, when it comes to #COVID19 symptom severity in children?

GOOD NEWS 🥳

Turns out there is barely any difference at all between Delta and Alpha in symptom duration, severity, or risk of “long covid”

Myth busted 💥 https://t.co/iPd9AedXaS

— Alasdair Munro (@apsmunro) October 7, 2021

 

---

É muito baixo o risco de inflamação cardíaca após vacina da Pfizer contra COVID.

12 Out, 2021 | 11:15h

Heart-inflammation risk from Pfizer COVID vaccine is very low – Nature

Estudos originais:

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

---